2of0:A (ASN5) to (GLY41) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 5 | ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN
2ohk:A (ASN5) to (GLY41) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 1- AMINO-ISOQUINOLINE | ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN
2ohl:A (ASN5) to (ALA43) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 2- AMINOQUINOLINE | ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN
2ohn:A (ASN5) to (GLY41) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH 4- (4-FLUOROBENZYL)PIPERIDINE | ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN
2ohp:A (ASN5) to (GLY41) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 3 | ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN
2ohq:A (ASN5) to (ALA43) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 4 | ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, TRANSMEMBRANE, ZYMOGEN
2oht:A (ASN5) to (GLY41) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 7 | ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN
2ohu:A (ASN5) to (GLY41) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8B | ALTERNATIVE SPLICING, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, SIGNAL, TRANSMEMBRANE, ZYMOGEN
2apr:A (GLY4) to (ALA44) STRUCTURE AND REFINEMENT AT 1.8 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS | HYDROLASE (ASPARTIC PROTEINASE)
2asi:A (GLY5) to (PRO47) ASPARTIC PROTEINASE | HYDROLASE, ASPARTYL PROTEASE, GLYCOPROTEIN, ZYMOGEN
3rth:A (ASN5) to (GLY41) STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(2-(3,3- DIMETHYLBUT-1-YNYL)PHENYL)QUINOLIN-2-AMINE | ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3rtm:A (ASN5) to (ALA43) STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3ru1:A (ASN5) to (ALA43) STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 3-(2- AMINOQUINOLIN-3-YL)-N-(CYCLOHEXYLMETHYL)PROPANAMIDE | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3rvi:A (ASN5) to (GLY41) STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 2-((2-AMINO-6-O- TOLYLQUINOLIN-3-YL)METHYL)-N-(CYCLOHEXYLMETHYL)PENTANAMIDE | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4h3f:A (ASN66) to (GLY102) STRUCTURE OF BACE BOUND TO 3-(5-((7AR)-2-IMINO-6-(6-METHOXYPYRIDIN-2- YL)-3-METHYL-4-OXOOCTAHYDRO-1H-PYRROLO[3,4-D]PYRIMIDIN-7A-YL) THIOPHEN-3-YL)BENZONITRILE | BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4h3g:A (ASN66) to (GLY102) STRUCTURE OF BACE BOUND TO 2-((7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2- YL)-2-IMINO-3-METHYL-4-OXOHEXAHYDRO-1H-PYRROLO[3,4-D]PYRIMIDIN-6(2H)- YL)NICOTINONITRILE | BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1apw:E (ALA1) to (PHE42) CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION STATE MIMICS BOUND TO PENICILLOPEPSIN: DIFLUOROSTATINE-AND DIFLUOROSTATONE-CONTAINING PEPTIDES | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4wy1:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 24B | BETA SECRETASE BACE PROTEASE
4wy6:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF HUMAN BACE-1 BOUND TO COMPOUND 36 | BACE BETA SECRETASE PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
2bju:A (ASN3) to (PRO43) PLASMEPSIN II COMPLEXED WITH A HIGHLY ACTIVE ACHIRAL INHIBITOR | PLASMEPSIN, ASPARTIC PROTEINASE, DRUG DESIGN, MALARIA, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, SIGNAL, ZYMOGEN
2bkt:A (THR2) to (PRO42) CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX | RENIN, ASPARTYL PROTEASE, HYDROLASE
2bkt:B (THR2) to (PRO42) CRYSTAL STRUCTURE OF RENIN-PF00257567 COMPLEX | RENIN, ASPARTYL PROTEASE, HYDROLASE
1od1:A (SER1) to (PHE44) ENDOTHIAPEPSIN PD135,040 COMPLEX | ACID PROTEINASE, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1oew:A (SER1) to (PHE44) ATOMIC RESOLUTION STRUCTURE OF NATIVE ENDOTHIAPEPSIN | HYDROLASE, ASPARTIC PROTEINASE MECHANISM, ATOMIC RESOLUTION, SUCCINIMIDE, ANISOTROPIC REFINEMENT
1oex:A (SER1) to (PHE44) ATOMIC RESOLUTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A HYDROXYETHYLENE TRANSITION STATE ANALOGUE INHIBITOR H261 | ASPARTIC PROTEINASE MECHANISM, ATOMIC RESOLUTION, SUCCINIMIDE, ANISOTROPIC REFINEMENT, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4hzt:A (ASN66) to (GLY102) STRUCTURE-BASED DESIGN OF NOVEL DIHYDROISOQUINOLINE BACE-1 INHIBITORS THAT DO NOT ENGAGE THE CATALYTIC ASPARTATES | ASPARTIC PROTEASE, HYDROLYSIS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4i0o:A (HIS268) to (TYR321) NUCLEOPORIN ELYS (AA1-494), MUS MUSCULUS | BETA PROPELLER, STRUCTURAL PROTEIN, NUCLEAR PORE COMPLEX, WD40 REPEAT, MRNA TRANSPORT
3skf:B (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BETA-SITE APP-CLEAVING ENZYME 1 (BACE-WT) COMPLEX WITH (2S)-2-((3S)-3-(ACETYLAMINO)-3-(BUTAN-2-YL)-2-OXOPYRROLIDIN-1- YL)-N-((2S,3R)-3-HYDROXY-4-((3-METHOXYBENZYL)AMINO)-1-PHENYLBUTAN-2- YL)-4-PHENYLBUTANAMIDE | ALZHEIMER'S DISEASE, BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3fns:A (PHE1) to (PRO41) CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM | HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, HORMONE, HYDROLASE
3fns:B (PHE1) to (PRO41) CRYSTAL STRUCTURE OF HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM | HISTO-ASPARTIC PROTEASE, HAP, PLASMEPSIN, ASPARTIC PROTEASE, HORMONE, HYDROLASE
3fnu:A (ASP2) to (PRO41) CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM | HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3fnu:B (ASP2) to (PRO41) CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM | HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3fnu:C (PHE1) to (PRO41) CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM | HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3fnu:D (PHE1) to (PRO41) CRYSTAL STRUCTURE OF KNI-10006 BOUND HISTO-ASPARTIC PROTEASE (HAP) FROM PLASMODIUM FALCIPARUM | HISTO-ASPARTIC PROTEASE,HYDROLASE, PLASMEPSIN, ASPARTIC PROTEASE, KNI, KNI-10006, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1cms:A (GLU2) to (PRO43) THE THREE-DIMENSIONAL STRUCTURE OF RECOMBINANT BOVINE CHYMOSIN AT 2.3 ANGSTROMS RESOLUTION | HYDROLASE(ACID PROTEINASE)
1czi:E (GLU-1) to (PRO41) CHYMOSIN COMPLEX WITH THE INHIBITOR CP-113972 | ACID PROTEINASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1dpj:A (HIS2) to (PRO41) THE STRUCTURE OF PROTEINASE A COMPLEXED WITH IA3 PEPTIDE INHIBITOR | PROTEINASE A, IA3 PEPTIDE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4xx3:A (ASN71) to (PRO113) RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM | ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RATS, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4xx3:B (ASN71) to (PRO113) RENIN IN COMPLEX WITH (S)-1-(3-(BENZYLCARBAMOYL)BENZYL)-4-ISOPROPYL-4- METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM | ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RATS, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4xx4:A (ASN71) to (PRO113) RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM | ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4xx4:B (ASN71) to (PRO113) RENIN IN COMPLEX WITH (4S)-4-ISOPROPYL-4-METHYL-6-OXO-1-(3-(2-OXO-4- PHENYLPYRROLIDIN-1-YL)BENZYL)TETRAHYDROPYRIMIDIN-2(1H)-IMINIUM | ANIMALS, ANTIHYPERTENSIVE AGENTS, BLOOD PRESSURE, DRUG DESIGN, ENZYME INHIBITORS, MODELS, MOLECULAR, PROTEIN CONFORMATION, RENIN, STRUCTURE-ACTIVITY RELATIONSHIP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4xxs:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 WITH A PYRAZOLE-SUBSTITUTED TETRAHYDROPYRAN THIOAMIDINE | AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ACID ENDOPEPTIDASES, DRUG DESIGN, STRUCTURE-ACTIVITY RELATIONSHIP
1ppl:E (ALA1) to (PHE42) CRYSTALLOGRAPHIC ANALYSIS OF TRANSITION-STATE MIMICS BOUND TO PENICILLOPEPSIN: PHOSPHORUS-CONTAINING PEPTIDE ANALOGUES | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3t7x:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1psa:A (ILE1) to (PRO41) STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1psa:B (ILE1) to (PRO41) STRUCTURE OF A PEPSIN(SLASH)RENIN INHIBITOR COMPLEX REVEALS A NOVEL CRYSTAL PACKING INDUCED BY MINOR CHEMICAL ALTERATIONS IN THE INHIBITOR | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1psn:A (ASP2) to (PRO41) THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN | HYDROLASE (ACID PROTEINASE)
1pso:E (VAL1) to (PRO41) THE CRYSTAL STRUCTURE OF HUMAN PEPSIN AND ITS COMPLEX WITH PEPSTATIN | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4y36:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 4 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4j0t:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-ETHOXY-PYRIDINE-2- CARBOXYLIC ACID [3-((R)-2-AMINO-5,5-DIFLUORO-4-METHYL-5,6-DIHYDRO-4H- [1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE | POTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4y35:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 290 | FAGMENT SCREENING, HYDROLASE, INHIBITION
4y37:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGEMENT 305 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y38:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B29 | FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE
4y3a:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 181 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4j0y:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R,5S)-2-AMINO-5-FLUORO-4-METHYL-5,6-DIHYDRO-4H- [1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE | PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4j0z:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S,5R)-2-AMINO-5-FLUORO-4-FLUOROMETHYL-5,6- DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE | PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4y3d:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 321 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3e:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 5 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4j1c:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((S)-2-AMINO-5,5-DIFLUORO-4-FLUOROMETHYL-5,6- DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE | PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4j1e:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S,6S)-2-AMINO-4-FLUOROMETHYL-6-TRIFLUOROMETHYL- 5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE | PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4j1f:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4S,6S)-2-AMINO-4-METHYL-6-TRIFLUOROMETHYL-5,6- DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]-AMIDE | PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4y3h:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 189 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y3j:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B30 | FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE
4j1i:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-CYANO-PYRIDINE-2- CARBOXYLIC ACID [3-((4R,5R,6R)-2-AMINO-5-FLUORO-4-METHYL-6- TRIFLUOROMETHYL-5,6-DIHYDRO-4H-[1,3]OXAZIN-4-YL)-4-FLUORO-PHENYL]- AMIDE | PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4y3l:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 205 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y3m:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 103 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y3n:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 273 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3t:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 207 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3p:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 17 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3q:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 109 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3r:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 306 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3s:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 266 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y3w:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 35 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3x:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 171 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y3y:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B42 | FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE
4y43:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 42 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y44:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 164 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y45:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 291 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y48:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B50 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y47:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 162 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y4b:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 323 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y4a:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 286 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y4c:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 158 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y4d:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B51 | FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE
4y4e:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 131 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y4j:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B97 | FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE
4y4t:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 114 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y4w:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 125 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y4z:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 73 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y51:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 52 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y53:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 54 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y54:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 56 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y56:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 58 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y57:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 63 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y58:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 260 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y5a:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 206 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y5b:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 261 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y5c:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 267 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y5e:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 268 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y5g:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 272 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y5l:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN ITS APO FORM | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y5k:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 274 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y5m:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 328 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y5n:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 337 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y5p:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 338 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y6m:A (ASN3) to (PRO43) STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG418 | PLASMEPSIN II HYDROXYETHYLAMINE-BASD INHIBITOR, HYDROLASE
3gw5:B (ILE11) to (PRO47) CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH A NOVEL INHIBITOR | RENIN, ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, SECRETED, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3tne:B (ASP1) to (VAL41) THE CRYSTAL STRUCTURE OF PROTEASE SAPP1P FROM CANDIDA PARAPSILOSIS IN COMPLEX WITH THE HIV PROTEASE INHIBITOR RITONAVIR | ASPARTIC ACID ENDOPEPTIDASES, CATALYTIC DOMAIN, RITONAVIR, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
4ya8:B (ASN3) to (PRO43) STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394 | PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE
4ya8:C (ASN3) to (PRO43) STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394 | PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE
4ya8:D (ASN3) to (PRO43) STRUCTURE OF PLASMEPSIN II FROM PLASMODIUM FALCIPARUM COMPLEXED WITH INHIBITOR PG394 | PLASMEPSIN II, MALARIA, INHIBITOR, HYDROLASE
4yck:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 211 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
3tpr:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 COMPLEXED WITH AN INHIBITOR | MEMAPSIN 2, PROTEASE, BETA-SECRETASE 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4yct:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 216 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4yd3:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 224 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4yd5:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 236 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4yd6:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 240 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
2ren:A (THR6) to (PRO47) STRUCTURE OF RECOMBINANT HUMAN RENIN, A TARGET FOR CARDIOVASCULAR- ACTIVE DRUGS, AT 2.5 ANGSTROMS RESOLUTION | HYDROLASE(ACID PROTEINASE)
3h0b:B (ASN5) to (GLY41) DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS | ASPARTYL PROTEASE, ALTERNATIVE SPLICING, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN
3h0b:C (ASN5) to (GLY41) DISCOVERY OF AMINOHETEROCYCLES AS A NOVEL BETA-SECRETASE INHIBITOR CLASS | ASPARTYL PROTEASE, ALTERNATIVE SPLICING, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN
1epo:E (SER-2) to (PHE41) ENDOTHIA ASPARTIC PROTEINASE (ENDOTHIAPEPSIN) COMPLEXED WITH CP-81,282 (MOR PHE NLE CHF NME) | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
2rmp:A (GLY5) to (PRO47) RMP-PEPSTATIN A COMPLEX | ASPARTIC PROTEINASE, PEPSTATIN A, ASPARTYL PROTEASE-PEPTIDE COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4jp9:A (ASN53) to (GLY89) SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4jpc:A (ASN53) to (GLY89) SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4jpe:A (ASN53) to (GLY89) SPIROCYCLIC BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1qrp:E (ASP2) to (PRO41) HUMAN PEPSIN 3A IN COMPLEX WITH A PHOSPHONATE INHIBITOR IVA-VAL-VAL- LEU(P)-(O)PHE-ALA-ALA-OME | ASPARTIC PROTEINASE, PHOSPHONATE INHIBITOR, TRANSITION STATE ANALOGUE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1f34:A (GLY2) to (PRO41) CRYSTAL STRUCTURE OF ASCARIS PEPSIN INHIBITOR-3 BOUND TO PORCINE PEPSIN | PROTEINASE-INHIBITOR COMPLEX, HYDROLASE/HYDROLASE INHIBITOR COMPLEX
3u6a:B (ASN5) to (GLY41) RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS | BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3u6a:C (ASN5) to (GLY41) RATIONAL DESIGN AND SYNTHESIS OF AMINOPIPERAZINONES AS BETA SECRETASE (BACE) INHIBITORS | BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1fbn:A (GLU2) to (ARG50) CRYSTAL STRUCTURE OF A FIBRILLARIN HOMOLOGUE FROM METHANOCOCCUS JANNASCHII, A HYPERTHERMOPHILE, AT 1.6 A | FIBRILLARIN, MJ PROTEINS, RIBOSOMAL RNA PROCESSING, SNORNP, STRUCTURAL GENOMICS, BSGC STRUCTURE FUNDED BY NIH, PROTEIN STRUCTURE INITIATIVE, PSI, BERKELEY STRUCTURAL GENOMICS CENTER, RIBOSOME
3u75:C (ALA230) to (ASP279) STRUCTURE OF E230A-FRUCTOFURANOSIDASE FROM SCHWANNIOMYCES OCCIDENTALIS COMPLEXED WITH FRUCTOSYLNYSTOSE | GLYCOSIDASE GH32, BETA-PROPELLER, HYDROLASE, CARBOHYDRATE/SUGAR BINDING, GLYCOSYLATIONS
2v00:A (SER1) to (PHE44) X-RAY CRYSTAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH COMPOUND 1 | FRAGMENT HIT, B- SECRETASE, ENDOTHIAPEPSIN, BACE, ZYMOGEN, PROTEASE, HYDROLASE, ISOCYTOSINE, ALZHEIMER'S DISEASE, FRAGMENT-BASED LEAD GENERATION, ASPARTYL PROTEASE, SURROGATE PROTEIN
2v11:C (THR6) to (PRO47) CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 6 | GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES
2v12:C (THR6) to (PRO47) CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 8 | GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES
2er7:E (SER-2) to (PHE41) X-RAY ANALYSES OF ASPARTIC PROTEINASES.III. THREE-DIMENSIONAL STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH A TRANSITION-STATE ISOSTERE INHIBITOR OF RENIN AT 1.6 ANGSTROMS RESOLUTION | HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ACID PROTEINASE
3udj:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE WITH COMPOUND 5 | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3udq:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE WITH COMPOUND 13 | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3ugg:B (CYS212) to (PRO265) CRYSTAL STRUCTURE OF A 6-SST/6-SFT FROM PACHYSANDRA TERMINALIS IN COMPLEX WITH 1-KESTOSE | FRUCTOSYLTRANSFERASE, GLYCOSIDE HYDROLASE FAMILY 32, TRANSFERASE
3ugh:B (CYS212) to (PRO265) CRYSTAL STRUCTURE OF A 6-SST/6-SFT FROM PACHYSANDRA TERMINALIS IN COMPLEX WITH 6-KESTOSE | FRUCTOSYLTRANSFERASE, GLYCOSIDE HYDROLASE FAMILY 32, TRANSFERASE
2va5:A (ASN5) to (GLY41) X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 8C | BASE, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, ALZHEIMER'S DISEASE, ALTERNATIVE SPLICING, MEMAPSIN 2, GLYCOPROTEIN, TRANSMEMBRANE, BETA-SECRETASE, ASPARTYL PROTEASE, ASPARTIC PROTEASE
4ke0:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13 | ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, AMYLOID PRECURSOR PROTEIN (APP), HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4ke0:B (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE- MACROCYCLIC INHIBITOR 13 | ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, AMYLOID PRECURSOR PROTEIN (APP), HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1g8s:A (ASP3) to (ARG50) METHANOCOCCUS JANNASCHII FIBRILLARIN PRE-RRNA PROCESSING PROTEIN | RRNA PROCESSING; RNA BINDING, RNA BINDING PROTEIN
3urj:A (SER1) to (PHE44) TYPE IV NATIVE ENDOTHIAPEPSIN | ASPARTIC PROTEINASE, PROTEOLYSIS, SECRETED., HYDROLASE
2viy:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(PENTYLSULFONYL)BENZAMIDE | ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE
2viz:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(2-OXO-1-PYRROLIDINYL)-5-(PROPYLOXY) BENZAMIDE | ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE
2vj6:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE | MEMBRANE, HYDROLASE, MEMAPSIN-2, GLYCOPROTEIN
2vj7:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH 3-(ETHYLAMINO)-N-((1S,2R)-2- HYDROXY-1-(PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL) METHYL)AMINO)PROPYL)-5-(2-OXO-1-PYRROLIDINYL)BENZAMIDE | ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, HYDROLASE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE
3hvg:B (ASN5) to (GLY41) STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH EV0 | PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, DISULFIDE BOND, TRANSMEMBRANE, ZYMOGEN
4zea:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B91 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
1gkt:A (SER1) to (PHE44) NEUTRON LAUE DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN COMPLEXED WITH TRANSITION STATE ANALOGUE INHIBITOR H261 | HYDROLASE-HYDROLASE INHIBITOR COMPLEX, PROTEASE-INHIBITOR, ASPARTIC PROTEINASE, HYDROLYSIS, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
2vnn:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5- HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE | HYDROLASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE
2g1s:A (SER3) to (PRO42) KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING | PROTEIN-LIGAND COMPLEXES, HYDROLASE
2g1s:B (SER3) to (PRO42) KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING | PROTEIN-LIGAND COMPLEXES, HYDROLASE
2g1y:A (SER3) to (PRO42) KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING | PROTEIN-LIGAND COMPLEXES, HYDROLASE
2g24:B (SER3) to (PRO42) KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING | PROTEIN-LIGAND COMPLEXES, HYDROLASE
2g26:A (SER3) to (PRO42) KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE "C" RING | PROTEIN-LIGAND COMPLEXES, HYDROLASE
1sme:B (SER2) to (PRO43) PLASMEPSIN II, A HEMOGLOBIN-DEGRADING ENZYME FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH PEPSTATIN A | ASPARTYL PROTEINASE, ASPARTIC PROTEINASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1smr:A (LEU0) to (PRO41) THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN | ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1smr:C (LEU0) to (PRO41) THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN | ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1smr:E (LEU0) to (PRO41) THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN | ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1smr:G (LEU0) to (PRO41) THE 3-D STRUCTURE OF MOUSE SUBMAXILLARY RENIN COMPLEXED WITH A DECAPEPTIDE INHIBITOR CH-66 BASED ON THE 4-16 FRAGMENT OF RAT ANGIOTENSINOGEN | ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
2vs2:A (SER1) to (PHE44) NEUTRON DIFFRACTION STRUCTURE OF ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR. | ACID PROTEINASE, ASPARTYL PROTEASE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4kup:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH 20MM ACYLHYDRAZONE INHIBITOR | HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1gvt:A (SER1) to (PHE44) ENDOTHIAPEPSIN COMPLEX WITH CP-80,794 | HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ASPARTIC PROTEINASE MECHANISM, TETRAHEDRAL INTERMEDIATE, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
1gvu:A (SER1) to (PHE44) ENDOTHIAPEPSIN COMPLEX WITH H189 | HYDROLASE, ASPARTIC PROTEINASE MECHANISM, ATOMIC RESOLUTION, Z TETRAHEDRAL INTERMEDIATE, ANISOTROPIC REFINEMENT, ASPARTYL P, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1gvv:A (SER1) to (PHE44) FIVE ATOMIC RESOLUTION STRUCTURES OF ENDOTHIAPEPSIN INHIBITOR COMPLEXES; IMPLICATIONS FOR THE ASPARTIC PROTEINASE MECHANISM | HYDROLASE-HYDROLASE INHIBITOR COMPLEX, ASPARTIC PROTEINASE MECHANISM, Z TETRAHEDRAL INTERMEDIATE, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
1gvx:A (SER1) to (PHE44) ENDOTHIAPEPSIN COMPLEXED WITH H256 | HYDROLASE, ASPARTIC PROTEINASE MECHANISM, TETRAHEDRAL INTERMEDIATE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3vf3:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BQQ711 | STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4l6b:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP128 | ASPARTATE PROTEASE, INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4l7g:A (ASN5) to (GLY41) DIETHYLAMINOSULFUR TRIFLUORIDE-MEDIATED INTRAMOLECULAR CYCLIZATION OF 2-HYDROXY-BENZYLUREAS TO FUSED BICYCLIC AMINOOXAZOLINE COMPOUNDS AND EVALUATION OF THEIR BIOCHEMICAL ACTIVITY AGAINST BETA-SECRETASE-1 (BACE1) | ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4lap:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH THIOPHEN-BASED INHIBITOR SAP114 | ASPARTATE PROTEASE, INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4lbt:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH 100MM ACYLHYDRAZONE INHIBITOR | HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4lc7:A (ASN66) to (GLY102) AMINOOXAZOLINE INHIBITOR OF BACE-1 | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4zsr:A (ASN5) to (GLY41) BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR | ASPARTYL, PROTEASE, BETA-SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4zsr:B (ASN5) to (GLY41) BACE CRYSTAL STRUCTURE WITH TRICYCLIC AMINOTHIAZINE INHIBITOR | ASPARTYL, PROTEASE, BETA-SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3ilf:A (LYS106) to (VAL142) CRYSTAL STRUCTURE OF PORPHYRANASE A (PORA) IN COMPLEX WITH NEO- PORPHYROTETRAOSE | GLYCOSIDE HYDROLASE FAMILY GH16, BETA-SANDWICH FOLD, JELLY ROLL, HYDROLASE-CARBOHYDRATE COMPLEX
3inf:A (ASN67) to (ALA105) BACE1 WITH THE AMINOHYDANTOIN COMPOUND 37 | BACE1, INHIBITOR, XRAY, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN
4lhh:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH 2MM ACYLHYDRAZONE INHIBITOR | HYDROLASE, ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3ivh:A (ASN66) to (GLY102) DESIGN AND SYNTHESIS OF POTENT BACE-1 INHIBITORS WITH CELLULAR ACTIVITY: STRUCTURE-ACTIVITY RELATIONSHIP OF P1 SUBSTITUENTS | ASPARTYL PROTEASE, BACE-1 INHIBITORS, ALZHEIMER'S DISEASE, STRUCTURE- BASED DRUG DESIGN, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN
2web:A (ALA1) to (PHE42) ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE INHIBITOR: METHYL(2S)-[1-(((N-FORMYL)-L- VALYL)AMINO-2-(2-NAPHTHYL)ETHYL)HYDROXYPHOSPHINYLOXY]-3- PHENYLPROPANOATE, SODIUM SALT | PENICILLOPEPSIN, PHOSPHONATE INHIBITOR, HYDROLASE
2wf0:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH 4-ETHYL-N-((1S,2R)-2-HYDROXY-1- (PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)-8-(2-OXO-1-PYRROLIDINYL)-6-QUINOLINECARBOXAMIDE | HYDROLASE, MEMAPSIN-2, POLYMORPHISM, GLYCOPROTEIN, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, TRANSMEMBRANE, BETA-SECRETASE, DISULFIDE BOND, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME
2wf1:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH 7-ETHYL-N-((1S,2R)-2-HYDROXY-3- (((3-(METHYLOXY)PHENYL(METHYL)AMINO)-1-(PHENYLMETHYL) PROPYL)-1-METHYL-3,4-DIHYDRO-1H-(1,2,5)THIADIAZEPINO(3,4,5- HI)INDOLE-9-CARBOXAMIDE 2,2-DIOXIDE | HYDROLASE, MEMAPSIN-2, POLYMORPHISM, GLYCOPROTEIN, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, TRANSMEMBRANE, BETA-SECRETASE, DISULFIDE BOND, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME
3ixj:A (ASN53) to (GLY89) CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR | BACE, BETA SECRETASE-1, INHIBITOR, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN, DISULFIDE BOND, POLYMORPHISM, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3ixj:C (ASN53) to (GLY89) CRYSTAL STRUCTURE OF BETA-SECRETASE 1 IN COMPLEX WITH SELECTIVE BETA-SECRETASE 1 INHIBITOR | BACE, BETA SECRETASE-1, INHIBITOR, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN, DISULFIDE BOND, POLYMORPHISM, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
2wf4:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH 6-ETHYL-1-METHYL-N-((1S)-2-OXO- 1-(PHENYLMETHYL)-3-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)PROPYL)- 1,3,4,6-TETRAHYDRO(1,2)THIAZEPINO(5,4,3-CD)INDOLE-8- CARBOXAMIDE 2,2-DIOXIDE | HYDROLASE, MEMAPSIN-2, POLYMORPHISM, GLYCOPROTEIN, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, TRANSMEMBRANE, BETA-SECRETASE, DISULFIDE BOND, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME
3vsx:A (ILE11) to (PRO47) HUMAN RENIN IN COMPLEX WITH COMPOUND 18 | RAS, HYPERTENSION, INHIBITOR, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3vv6:A (ASN5) to (ALA43) CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-3-METHYL-6- ((1S, 2R)-2-PHENYLCYCLOPROPYL)PYRIMIDIN-4(3H)-ONE | ASPARTYL PROTEASE, BACE, BATA SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3vv7:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH 2-AMINO-6-((1S,2R)- 2-(3'-METHOXYBIPHENYL-3-YL)CYCLOPROPYL)-3-METHYLPYRIMIDIN-4(3H)-ONE | ASPARTYL PROTEASE, BASE, BETA-SECRETASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3vyf:A (ILE11) to (PRO47) HUMAN RENIN IN COMPLEX WITH INHIBITOR 9 | ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3vyf:B (ILE11) to (PRO47) HUMAN RENIN IN COMPLEX WITH INHIBITOR 9 | ASPARTYL PROTEASE, RAS, HYPERTENSION, INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1uh7:A (GLY4) to (ALA44) CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 4.6 | PEPSIN, ASPARTIC PROTEINASE, HYDROLASE
1uh8:A (GLY4) to (ALA44) CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 8.0 | PEPSIN, ASPARTIC PROTEINASE, HYDROLASE
2i4q:A (ASN0) to (PRO42) HUMAN RENIN/PF02342674 COMPLEX | RENIN INHIBITOR, PROTEIN-LIGAND COMPLEX, HYDROLASE
2igx:A (ASN3) to (PRO43) ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II | ACHIRAL INHIBITOR, HYDROLASE
2igy:A (ASN3) to (PRO43) ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II | ACHIRAL INHIBITOR, HYDROLASE
2igy:B (ASN3) to (PRO43) ACHIRAL, CHEAP AND POTENT INHIBITORS OF PLASMEPSINS II | ACHIRAL INHIBITOR, HYDROLASE
2iko:A (ASN0) to (PRO42) CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR | RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE
2iko:B (ASN0) to (PRO42) CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR | RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE
2iku:A (ILE6) to (PRO42) CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS | RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE
2iku:B (ASN0) to (PRO42) CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITORS | RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE
2il2:A (ASN0) to (PRO42) CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR | RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE
2il2:B (ASN0) to (PRO42) CRYSTAL STRUCTURE OF HUMAN RENIN COMPLEXED WITH INHIBITOR | RENIN, INHIBITORS, DRUG DESIGN, HYDROLASE
5apr:E (GLY4) to (ALA44) STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
2xfi:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-((METHYLSULFONYL)(PHENYL)AMINO) BENZAMIDE | HYDROLASE, PROTEASE, ZYMOGEN
2xfj:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH N-((1S,2R)-3-(((1S)-2-( CYCLOHEXYLAMINO)-1-METHYL-2-OXOETHYL)AMINO)-2-HYDROXY-1-( PHENYLMETHYL)PROPYL)-3-(ETHYLAMINO)-5-(2-OXO-1- PYRROLIDINYL)BENZAMIDE | ZYMOGEN, PROTEASE, HYDROLASE
3wz6:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (5) | ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3wz8:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH GEWALD REACTION-DERIVED INHIBITOR (8) | ASPARTIC PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4n00:A (ASN66) to (GLY102) DISCOVERY OF 7-THP CHROMANS: BACE1 INHIBITORS THAT REDUCE A-BETA IN THE CNS | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5bmt:B (THR46) to (SER103) CRYSTAL STRUCTURE OF AN UNCHARACTERIZED PROTEIN (PARMER_03598) FROM PARABACTEROIDES MERDAE ATCC 43184 AT 1.50 A RESOLUTION | IMMUNOGLOBULIN-LIKE FOLD, STRUCTURAL GENOMICS, JOINT CENTER FOR STRUCTURAL GENOMICS, JCSG, PROTEIN STRUCTURE INITIATIVE, PSI- BIOLOGY, UNKNOWN FUNCTION
1w6h:B (ASP4) to (PRO43) NOVEL PLASMEPSIN II-INHIBITOR COMPLEX | MALARIA, DRUG, ASPARTIC PROTEASE, PLASMEPSIN, HYDROLASE, GLYCOPROTEIN
1w6i:C (ASN3) to (PRO43) PLASMEPSIN II-PEPSTATIN A COMPLEX | MALARIA, DRUG, ASPARTIC PROTEASE, PLASMEPSIN, GLYCOPROTEIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1wkr:A (ALA1) to (GLY41) CRYSTAL STRUCTURE OF ASPARTIC PROTEINASE FROM IRPEX LACTEUS | HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1xdh:A (ASN3) to (PRO43) STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH PEPSTATIN A | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1xe5:A (ASN3) to (PRO43) STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1xe5:B (ASP4) to (PRO43) STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1xe6:A (ASN3) to (PRO43) STRUCTURE OF PLASMEPSIN II IN COMPLEX OF AN PEPSTATIN ANALOGUE | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5clm:A (ASN5) to (GLY41) 1,4-OXAZINE BACE1 INHIBITORS | BACE1 PROTEASE INHIBITOR, ORALLY BIOAVAILABLE, BRAIN PENETRANT, PROTEROS BIOSTRUCTURES GMBH, HYDROLASE
1ls5:A (ASN3) to (PRO43) CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A | EUKARYOTIC ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1ls5:B (ASP4) to (PRO43) CRYSTAL STRUCTURE OF PLASMEPSIN IV FROM P. FALCIPARUM IN COMPLEX WITH PEPSTATIN A | EUKARYOTIC ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
2zht:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 AT PH 4.5 | PH 4.5, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN
2zhu:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 AT PH 5.0 | PH 5.0, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN
2zhv:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 AT PH 7.0 | PH 7.0, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN
1m43:B (ASN3) to (PRO43) CRYSTAL STRUCTURE OF PMII IN COMPLEX WITH PEPSTATIN A TO 2.4 A | PLASMEPSIN II, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
2zjh:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-(1-BENZYL-PIPERIDIN-4-YL)-4-MERCAPTO-BUTYRAMIDE | BACE1, SMALL-MOLECULE INHIBITOR, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN
2zjl:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-BROMO-2,3-DIMETHOXY-BENZYL)-PIPERIDIN- 4-YL]-4-MERCAPTO-BUTYRAMIDE | BACE1, SMALL-MOLECULE INHIBITOR, TETHERING, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN
2zjn:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(5-CHLORO-2-ISOPROPOXY-3-METHOXY-BENZYL)- PIPERIDIN-4-YL]-2-(2-METHYL-4-SULFAMOYL-PHENOXY)-ACETAMIDE | BACE1, SMALL-MOLECULE INHIBITOR, FRAGMENT-BASED DISCOVERY, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN
1me6:B (ASN3) to (PRO43) CRYSTAL STRUCTURE OF PLASMEPSIN II, AN ASPARTYL PROTEASE FROM PLASMODIUM FALCIPARUM, IN COMPLEX WITH A STATINE-BASED INHIBITOR | PROTEIN-LIGAND COMPLEX, HYDROLASE
3kn0:A (ASN66) to (GLY102) STRUCTURE OF BACE BOUND TO SCH708236 | BACE1, ALZHEIMER'S, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, DISULFIDE BOND, ENDOPLASMIC RETICULUM, ENDOSOME, GLYCOPROTEIN, GOLGI APPARATUS, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN
1mpp:A (GLY-1) to (PRO41) X-RAY ANALYSES OF ASPARTIC PROTEINASES. V. STRUCTURE AND REFINEMENT AT 2.0 ANGSTROMS RESOLUTION OF THE ASPARTIC PROTEINASE FROM MUCOR PUSILLUS | HYDROLASE(ACID PROTEINASE)
1y9g:A (GLU241) to (ASP292) CRYSTAL STRUCTURE OF EXO-INULINASE FROM ASPERGILLUS AWAMORI COMPLEXED WITH FRUCTOSE | EXO-INULINASE, ASPERGILLUS AWAMORI, GLYCOSIDE HYDROLASE FAMILY 32, CRYSTALLOGRAPHIC STRUCTURE, COMPLEX WITH FRUCTOSE, HYDROLASE
5dpz:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 31 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dq1:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 34 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dq4:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 66 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dq5:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 209 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dr0:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 203 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dr1:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 278 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dr4:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 231 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dr8:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 330 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4pzw:A (ASN66) to (GLY102) SYNTHESIS, CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4pzx:A (ASN66) to (GLY102) SYNTHESIS, CHARACTERIZATION AND PK/PD STUDIES OF A SERIES OF SPIROCYCLIC PYRANOCHROMENE BACE1 INHIBITORS | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3apr:E (GLY4) to (ALA44) BINDING OF A REDUCED PEPTIDE INHIBITOR TO THE ASPARTIC PROTEINASE FROM RHIZOPUS CHINENSIS. IMPLICATIONS FOR A MECHANISM OF ACTION | HYDROLASE, ASPARTIC PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4azy:A (ASN5) to (ALA43) DESIGN AND SYNTHESIS OF BACE1 INHIBITORS WITH IN VIVO BRAIN REDUCTION OF BETA-AMYLOID PEPTIDES (COMPOUND 10) | HYDROLASE, AMINOISOINDOLE, ALZHEIMER'S DISEASE
4b0q:A (ASN5) to (ALA43) LEAD GENERATION OF BACE1 INHIBITORS BY COUPLING NON-AMIDINE NEW WARHEADS TO A KNOWN BINDING SCAFFOLD | HYDROLASE, BACE1 INHIBITORS, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN
4b1d:A (ASN5) to (ALA43) NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN | HYDROLASE, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN, INHIBITOR
4b1e:A (ASN5) to (GLY41) NEW AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM RATIONAL DESIGN TO AB-LOWERING IN BRAIN | HYDROLASE, STRUCTURE-BASED DRUG DESIGN
3lzy:A (SER1) to (PHE44) CRYSTAL STRUCTURE OF ENDOTHIAPESIN IN COMPLEX WITH XENON | PROTEIN-XE COMPLEX, HYDROLASE, B-SECRETASE, ENDOTHIAPEPSIN, ASPARTYL PROTEASE, PROTEASE, ZYMOGEN
4b70:A (ASN5) to (GLY41) AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN | HYDROLASE, HYDROLASE INHIBITOR, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN
4b72:A (ASN5) to (ALA43) AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN | HYDROLASE, HYDROLASE INHIBITOR, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN
2ade:A (GLY198) to (PRO253) CRYSTAL STRUCTURE OF FRUCTAN 1-EXOHYDROLASE IIA FROM CICHORIUM INTYBUS IN COMPLEX WITH FRUCTOSE | FIVE FOLD BETA PROPELLER, HYDROLASE
2aez:A (PRO203) to (PRO253) CRYSTAL STRUCTURE OF FRUCTAN 1-EXOHYDROLASE IIA (E201Q) FROM CICHORIUM INTYBUS IN COMPLEX WITH 1-KESTOSE | FIVE FOLD BETA PROPELLER, HYDROLASE
2aey:A (GLY198) to (PRO253) CRYSTAL STRUCTURE OF FRUCTAN 1-EXOHYDROLASE IIA FROM CICHORIUM INTYBUS IN COMPLEX WITH 2,5 DIDEOXY-2,5-IMMINO-D-MANNITOL | FIVE FOLD BETA PROPELLER, HYDROLASE
5enk:A (ASN53) to (GLY89) COMPOUND 18 | BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5enm:A (ASN53) to (GLY89) COMPOUND 10 | BACE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3msj:A (ASN5) to (GLY41) STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR | PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3msj:B (ASN5) to (GLY41) STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR | PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3msj:C (ASN5) to (GLY41) STRUCTURE OF BACE (BETA SECRETASE) IN COMPLEX WITH INHIBITOR | PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3msk:A (ASN5) to (GLY41) FRAGMENT BASED DISCOVERY AND OPTIMISATION OF BACE-1 INHIBITORS | PROTEASE, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, ASPARTYL PROTEASE, BASE, BETA-SECRETASE, GLYCOPROTEIN, HYDROLASE, MEMAPSIN 2, AMYLOID PRECURSOR PROTEIN SECRETASES, ASPARTIC ENDOPEPTIDASES, FRAGMENT- BASED DRUG DESIGN, FLUORESCENCE POLARISATION, TRANSMEMBRANE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5ez3:D (TRP223) to (GLY283) CRYSTAL STRUCTURE ACYL-COA DEHYDROGENASE FROM BRUCELLA MELITENSIS IN COMPLEX WITH FAD | SSGCID, DEHYDROGENASE, FAD, STRUCTURAL GENOMICS, SEATTLE STRUCTURAL GENOMICS CENTER FOR INFECTIOUS DISEASE, OXIDOREDUCTASE
5ezz:A (ASN66) to (ALA104) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-CHLORO-3- PYRIDYL)PHENYL]-4-[4-(DIFLUOROMETHOXY)-3-METHYL-PHENYL]-5H-OXAZOL-2- AMINE | PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX, HYDROLASE- INHIBITOR COMPLEX
5f01:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR,2SR)-2-((R)-2-AMINO- 5,5-DIFLUORO-4-METHYL-5,6-DIHYDRO-4H-1,3-OXAZIN-4-YL)-N-(3- CHLOROQUINOLIN-8-YL)CYCLOPROPANECARBOXAMIDE | PROTEASE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX, HYDROLASE
3bug:A (ASN5) to (GLY41) BACE-1 COMPLEXED WITH COMPOUND 3 | ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, BETA-SECRETASE, MEMAPSIN 2, FRAGMENT SCREEN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN
4r5n:A (ASN66) to (GLY102) 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3ckr:C (ASN5) to (ALA43) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR | BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN
3cms:A (GLU-1) to (PRO41) ENGINEERING ENZYME SUB-SITE SPECIFICITY: PREPARATION, KINETIC CHARACTERIZATION AND X-RAY ANALYSIS AT 2.0-ANGSTROMS RESOLUTION OF VAL111PHE SITE-MUTATED CALF CHYMOSIN | HYDROLASE, ACID PROTEINASE
3nvk:I (MET1) to (ILE50) STRUCTURAL BASIS FOR SUBSTRATE PLACEMENT BY AN ARCHAEAL BOX C/D RIBONUCLEOPROTEIN PARTICLE | NOP DOMAIN KINK TURN METHYL TRANSFERASE, RIBOSOME BIOGENESIS SPLICEOSOME BIOGENESIS, TRANSFERASE-RNA COMPLEX
3nvm:B (MET1) to (ASN52) STRUCTURAL BASIS FOR SUBSTRATE PLACEMENT BY AN ARCHAEAL BOX C/D RIBONUCLEOPROTEIN PARTICLE | NOP DOMAIN, METHYLTRANSFERASE, RIBOSOME BIOGENESIS, SPLICEOSOME BIOGENESIS, TRANSFERASE
4rrn:A (ASN66) to (GLY102) 8-TETRAHYDROPYRAN-2-YL CHROMANS: HIGHLY SELECTIVE BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1 (BACE1) INHIBITORS | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4cku:A (ASN3) to (PRO43) THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR | HYDROLASE, MALARIA, DRUG DESIGN
4cku:B (ASN3) to (PRO43) THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR | HYDROLASE, MALARIA, DRUG DESIGN
4cku:C (ASP4) to (PRO43) THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR | HYDROLASE, MALARIA, DRUG DESIGN
4cku:D (ASP4) to (PRO43) THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR | HYDROLASE, MALARIA, DRUG DESIGN
4cku:E (ASP4) to (PRO43) THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR | HYDROLASE, MALARIA, DRUG DESIGN
4cku:F (GLU7) to (PRO43) THREE DIMENSIONAL STRUCTURE OF PLASMEPSIN II IN COMPLEX WITH HYDROXYETHYLAMINE-BASED INHIBITOR | HYDROLASE, MALARIA, DRUG DESIGN
4ryc:A (ASN-1) to (PRO41) RENIN IN COMPLEXED WITH 4-METHOXY-3-(3-METHOXYPROPOXY)-N-{[(3S,4S)-4- {[(4-METHYLPHENYL)SULFONYL]AMINO}PYRROLIDIN-3-YL]METHYL}-N-(PROPAN-2- YL)BENZAMIDE INHIBITOR | HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4cms:A (GLU-1) to (PRO41) X-RAY ANALYSES OF ASPARTIC PROTEINASES IV. STRUCTURE AND REFINEMENT AT 2.2 ANGSTROMS RESOLUTION OF BOVINE CHYMOSIN | HYDROLASE (ACID PROTEINASE)
4ryg:A (ILE5) to (PRO41) RENIN IN COMPLEXED WITH N-({(3S,4S)-4-[(BENZYLSULFONYL) AMINO]PYRROLIDIN-3-YL}METHYL)-4-METHOXY-3-(3-METHOXYPROPOXY)-N- (PROPAN-2-YL)BENZAMIDE INHIBITOR | HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4s1g:A (ASN71) to (PRO113) REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM | ASPARTIC PROTEASE, BLOOD PREASURE, ANGIOTENSINOGEN, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
4s1g:B (ASN71) to (PRO113) REIN IN COMPLEX WITH (S)-1-(3-FLUORO-5-(((S)-1-PHENYLETHYL)CARBAMOYL) BENZYL)-4-ISOPROPYL-4-METHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM | ASPARTIC PROTEASE, BLOOD PREASURE, ANGIOTENSINOGEN, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
3oag:C (VAL10) to (PRO47) DESIGN AND OPTIMIZATION OF NEW PIPERIDINES AS RENIN INHIBITORS | HYDROLASE, PROTEASE, GLYCOSILATION, BLOOD, HYDROLASE - HYDROLASE INHIBITOR COMPLEX
3d91:A (ASN5) to (PRO47) HUMAN RENIN IN COMPLEX WITH REMIKIREN | RENIN, REMIKIREN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, SECRETED, ZYMOGEN
3d91:B (ASN5) to (PRO47) HUMAN RENIN IN COMPLEX WITH REMIKIREN | RENIN, REMIKIREN, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, SECRETED, ZYMOGEN
3oot:A (THR0) to (PRO41) CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES | RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE
4d85:A (ASN7) to (GLY43) CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BVI151 | BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4d88:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXQ490 | BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4d89:A (ASN53) to (GLY89) CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BXD552, DERIVED FROM A SOAKING EXPERIMENT | BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3oqk:A (THR0) to (PRO41) CRYSTAL STRUCTURE ANALYSIS OF RENIN-INDOLE-PIPERAZIN INHIBITOR COMPLEXES | RENIN HUMAN, ASPARTYL PROTEASE, RENIN INHIBITION, HYPERTENSION, HYDROLASE
5hct:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH BIACYLHYDRAZONE | HYDROLASE, INHIBITION
5hd0:A (ASN66) to (GLY102) BACE-1 IN COMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUOROPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3,4- D]PYRIMIDIN-2-IMINIUM | ASPARTYL PROTEASE, BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1, BETA-SITE APP CLEAVING ENZYME 1, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5hdu:A (ASN66) to (GLY102) BACE-1 INCOMPLEX WITH (7AR)-7A-(4-(3-CYANOPHENYL)THIOPHEN-2-YL)-6-(5- FLUORO-4-METHOXYPYRIMIDIN-2-YL)-3-METHYL-4-OXOOCTAHYDRO-2H-PYRROLO[3, 4-D]PYRIMIDIN-2-IMINIUM | ALZHEIMER'S, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3own:A (ASN2) to (PRO44) POTENT MACROCYCLIC RENIN INHIBITORS | RENIN, PROTEASE, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3own:B (ASN2) to (PRO44) POTENT MACROCYCLIC RENIN INHIBITORS | RENIN, PROTEASE, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4dh6:A (ASN5) to (GLY41) STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH (2R)-N-((2S,3R)- 1-(BENZO[D][1,3]DIOXOL-5-YL)-3-HYDROXY-4-((S)-6'-NEOPENTYL-3',4'- DIHYDROSPIRO[CYCLOBUTANE-1,2'-PYRANO[2,3-B]PYRIDINE]-4'-YLAMINO) BUTAN-2-YL)-2-METHOXYPROPANAMIDE | BACE-1, BETA-SECRETASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4di2:B (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH HYDROXYETHYLAMINE INHIBITOR 37 | MEMAPSIN-2, ALZHEIMER'S DISEASE, PROTEASE, BETA-SITE AMYLOID PRECURSOR PROTEIN CLEAVING ENZYME 1, APP, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4dpf:A (ASN53) to (GLY89) BACE-1 IN COMPLEX WITH A HEA-MACROCYCLIC TYPE INHIBITOR | BACE1, ASP2, BACE, MACROCYCLE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4dpi:A (ASN53) to (GLY89) BACE-1 IN COMPLEX WITH HEA-MACROCYCLIC INHIBITOR, MV078512 | BACE1, ASP2, BACE, MACROCYCLE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pb5:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pbd:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pbz:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pcw:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pep:A (ILE1) to (PRO41) REVISED 2.3 ANGSTROMS STRUCTURE OF PORCINE PEPSIN. EVIDENCE FOR A FLEXIBLE SUBDOMAIN | HYDROLASE (ACID PROTEINASE)
3pgi:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pi0:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pld:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pm4:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pmu:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pmy:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3prs:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH RITONAVIR | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3psy:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH AN INHIBITOR BASED ON THE GEWALD REACTION | HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pww:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH SAQUINAVIR | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3q4b:A (ASN-1) to (PRO41) CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS | ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3q5h:A (ASN-1) to (PRO41) CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS | ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
3q5h:B (THR0) to (PRO41) CLINICALLY USEFUL ALKYL AMINE RENIN INHIBITORS | ASPARTATE PROTEASE, HYPERTENSION, RENIN EXPRESSION, RENIN INHIBITOR, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, GLYCOPROTEIN, MEMBRANE, PROTEASE, SECRETED, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
3q6y:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A PYRROLIDINE BASED INHIBITOR | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4ewo:A (ASN53) to (GLY89) DESIGN AND SYNTHESIS OF POTENT HYDROXYETHYLAMINE (HEA) BACE-1 INHIBITORS | BACE, BETA-SECRETASE, STATINE, INHIBITOR, ASPARTYL PROTEASE, GLYCOPROTEIN, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN, HYDROLASE- HYDROLASE INHIBITOR COMPLEX
3qrv:A (ALA0) to (PRO41) CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM | ASPARTIC PROTEASE, MALARIA, HYDROLASE
3qrv:B (THR5) to (PRO41) CRYSTAL STRUCTURE OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM | ASPARTIC PROTEASE, MALARIA, HYDROLASE
3qs1:B (ASP2) to (PRO41) CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM | ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3qs1:C (GLY1) to (PRO41) CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM | ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3qs1:D (GLY1) to (PRO41) CRYSTAL STRUCTURE OF KNI-10006 COMPLEX OF PLASMEPSIN I (PMI) FROM PLASMODIUM FALCIPARUM | ASPARTIC PROTEASE, MALARIA, KNI, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3r1g:B (ASN66) to (GLY102) STRUCTURE BASIS OF ALLOSTERIC INHIBITION OF BACE1 BY AN EXOSITE- BINDING ANTIBODY | ASPARTAL PROTEASE, PROTEIN BINDING
4fm7:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE WITH COMPOUND 14G | ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4frj:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE1 IN COMPLEX WITH AMINOOXAZOLINE XANTHENE 9L | MEMBRANE PROTEIN, ALZHEIMER'S DISEASE, ASPARTIC PROTEASE, HYDROLASE- INHIBITOR COMPLEX
4frs:A (ASN66) to (GLY102) STRUCTURE OF BACE IN COMPLEX WITH (S)-4-(3-CHLORO-5-(5-(PROP-1-YN-1- YL)PYRIDIN-3-YL)THIOPHEN-2-YL)-1,4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN- 2(1H)-IMINIUM | ALZHEIMER'S, ASPARTYL PROTEASE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4fs4:A (ASN66) to (GLY102) STRUCTURE OF BACE BOUND TO (S)-4-(3'-METHOXY-[1,1'-BIPHENYL]-3-YL)-1, 4-DIMETHYL-6-OXOTETRAHYDROPYRIMIDIN-2(1H)-IMINIUM | BACE1, ALZHEIMERS, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gj5:A (THR0) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5) | RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gj5:B (ASN-1) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AMQ838 (COMPOUND 5) | RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gj8:A (ASN-1) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3) | RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gj8:B (THR1) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH PKF909-724 (COMPOUND 3) | RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gja:A (ILE5) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYL747 (COMPOUND 5) | RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gjc:A (ILE5) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9) | RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gjc:B (ASN-1) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BCH965 (COMPOUND 9) | RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gjd:A (ILE5) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-BGQ311 (COMPOUND 12) | RENIN INHIBITOR, FRAGMENT BASED SCREENING, 3,5-DISUBSTITUTED PIPERIDINES, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gmi:A (ASN5) to (GLY41) BACE-1 IN COMPLEX WITH HEA-TYPE MACROCYCLIC INHIBITOR, MV078571 | BACE-1, ASP2, BACE, MACROCYCLE, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5koq:A (THR6) to (PRO47) DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR | PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5koq:B (ILE11) to (PRO47) DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR | PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5kos:A (ASN5) to (PRO47) DISCOVERY OF TAK-272: A NOVEL, POTENT AND ORALLY ACTIVE RENIN IN- HIBITOR | PROTEIN-INHIBITOR COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5oyq:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 1 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oyr:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 2 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oys:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 3 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oyt:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 4 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oyu:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 5 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oyv:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 6 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oyw:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 7 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oyx:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 8 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oyy:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 9 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oyz:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 10 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz0:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 11 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz1:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 12 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz2:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 13 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz3:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 14 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz5:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 16 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz6:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 17 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz7:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 18 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz8:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 19 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oz9:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 20 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oza:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 21 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozb:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 22 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozc:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 23 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozd:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 24 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5oze:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 25 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozf:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 26 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozg:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 27 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozh:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 28 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozi:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 29 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozk:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 31 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozl:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 32 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozm:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 33 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozn:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 34 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozo:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 35 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozp:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 36 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozq:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 37 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozr:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 38 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozs:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 39 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozt:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 40 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozu:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 41 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozv:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 42 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozw:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 43 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozx:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 44 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozy:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 45 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozz:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 46 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p00:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 47 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p02:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 49 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p03:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 50 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p04:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 51 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p06:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 53 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p07:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 54 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p08:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 55 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p09:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 56 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 58 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 59 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 60 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 62 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 63 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 64 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 65 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 66 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 67 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 68 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 69 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 70 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 71 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0p:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 72 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 73 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 74 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 75 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 76 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 77 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 78 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0x:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 80 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0y:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 81 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0z:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 82 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p10:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 83 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p11:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 84 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p12:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 85 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p14:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 87 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p15:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 88 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p16:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 89 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p17:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 90 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p18:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 91 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p19:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 92 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 93 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 94 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 96 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 97 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 98 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 99 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 101 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 102 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 103 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 104 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 105 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1p:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 108 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 110 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 111 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 113 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1w:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 115 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1x:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 116 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1y:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 117 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1z:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 118 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p20:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 119 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p22:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 120 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p23:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 121 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p24:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 122 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p25:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 123 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p26:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 124 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p27:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 125 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p28:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 126 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p29:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 127 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 129 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 131 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 133 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 134 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 135 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 138 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 139 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 140 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 141 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 142 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 143 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 144 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 146 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 147 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 148 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2w:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 149 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2x:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 150 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2z:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 152 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p30:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 153 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p31:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 154 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p32:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 155 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p33:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 156 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p34:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 157 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p35:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 158 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p36:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 159 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p37:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 160 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p38:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 161 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 164 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 165 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 166 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 167 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 169 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 171 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 172 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 173 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 174 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 175 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 176 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 177 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3p:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 178 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 179 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 180 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 181 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 182 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 183 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 184 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3w:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 185 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3x:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 186 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3y:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 187 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3z:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 188 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p40:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 189 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p41:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 190 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p42:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 191 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p43:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 192 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p44:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 193 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p45:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 194 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p46:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 195 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p47:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 196 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p48:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 197 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p49:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 198 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 199 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 200 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 201 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 202 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 203 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 204 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 205 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 206 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 207 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 208 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 209 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 210 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 211 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 213 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4p:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 214 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 215 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 216 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 217 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 218 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 220 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4w:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 221 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4y:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 223 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4z:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 224 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p53:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 228 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p54:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 229 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p55:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 230 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p56:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 231 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p58:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 233 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p59:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 234 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 235 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 237 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 238 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 239 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 240 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 241 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 242 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 243 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 244 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 245 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 246 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 247 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 248 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 249 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 251 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 252 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 253 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 254 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 255 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 256 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5w:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 257 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5x:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 258 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5y:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 259 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5z:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 260 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p61:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 262 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p62:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 263 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p63:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 264 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p64:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 265 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p65:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 266 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p66:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 267 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p68:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 269 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 271 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 273 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 274 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 275 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 277 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 278 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 279 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 280 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 281 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 282 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 283 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 284 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 285 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6p:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 286 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 287 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 288 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 289 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 290 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 291 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 292 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6w:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 293 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6x:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 294 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6y:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 295 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6z:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 296 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p70:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 297 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p71:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 298 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p72:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 299 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p75:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 302 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p76:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 303 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p77:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 304 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p78:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 305 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 307 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 308 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 309 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 310 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 311 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 315 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 316 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 319 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 320 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 321 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7p:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 322 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 323 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 324 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 326 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 327 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 328 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7w:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 329 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7x:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 330 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7y:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 331 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7z:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 332 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p80:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 333 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p81:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 334 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p82:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 335 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p83:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 336 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p84:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 337 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p85:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 338 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p86:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 339 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p87:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 340 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p88:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 341 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p89:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 342 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 343 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 344 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 345 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8d:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 346 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 347 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 348 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 350 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 352 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 353 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 354 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8m:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 355 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 356 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 357 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8p:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 358 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8r:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 360 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 361 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 362 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 363 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 364 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5sxn:A (ASN5) to (PRO47) STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS | PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5sxn:B (ASN5) to (PRO47) STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS | PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5sy3:A (ASN5) to (PRO47) STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS | PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5sz9:A (THR6) to (PRO47) STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS | PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5sz9:B (THR6) to (PRO47) STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS | PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5t4s:B (ILE11) to (PRO47) NOVEL APPROACH OF FRAGMENT-BASED LEAD DISCOVERY APPLIED TO RENIN INHIBITORS | PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
6apr:E (GLY4) to (ALA44) STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3rsx:A (ASN5) to (GLY41) STRUCTURE OF BACE-1 (BETA-SECRETASE) IN COMPLEX WITH 6-(THIOPHEN-3- YL)QUINOLIN-2-AMINE | ASPARTIC PROTEASE, ASPARTYL PROTEASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
1apt:E (ALA1) to (PHE42) CRYSTALLOGRAPHIC ANALYSIS OF A PEPSTATIN ANALOGUE BINDING TO THE ASPARTYL PROTEINASE PENICILLOPEPSIN AT 1.8 ANGSTROMS RESOLUTION | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4i0j:A (ASN66) to (GLY102) SPR AND STRUCTURAL ANALYSIS YIELD INSIGHT TOWARDS MECHANISM OF INHIBITION OF BACE INHIBITORS | BACE ASP PROTEASE, HYDROLYSIS,, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
2c62:A (ALA62) to (PRO98) CRYSTAL STRUCTURE OF THE HUMAN TRANSCRIPTION COFACTOR PC4 IN COMPLEX WITH SINGLE-STRANDED DNA | TRANSCRIPTION COFACTOR, SINGLE-STRANDED DNA, PROTEIN-DNA COMPLEX, DNA UNWINDING, ACTIVATOR, DNA-BINDING, NUCLEAR PROTEIN, PHOSPHORYLATION, TRANSCRIPTION, TRANSCRIPTION REGULATION
2c62:B (ALA62) to (PRO98) CRYSTAL STRUCTURE OF THE HUMAN TRANSCRIPTION COFACTOR PC4 IN COMPLEX WITH SINGLE-STRANDED DNA | TRANSCRIPTION COFACTOR, SINGLE-STRANDED DNA, PROTEIN-DNA COMPLEX, DNA UNWINDING, ACTIVATOR, DNA-BINDING, NUCLEAR PROTEIN, PHOSPHORYLATION, TRANSCRIPTION, TRANSCRIPTION REGULATION
4y39:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 75 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y3f:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 78 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3g:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 285 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y3z:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 41 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y41:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 112 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y4g:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B53 | FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE
4y4u:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 14 | FRAGMENT SCREENING, ASPARTIC PROTEASE, INHIBITION, HYDROLASE
4y4x:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 51 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4y50:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 81 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
1e81:E (SER-2) to (PHE41) ENDOTHIAPEPSIN COMPLEX WITH RENIN INHIBITOR MERCK-KGAA-EMD61395 | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4yd4:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 227 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4yd7:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 255 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
2v0z:C (ASN-1) to (PRO41) CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN) | GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES
2v0z:O (ILE5) to (PRO41) CRYSTAL STRUCTURE OF RENIN WITH INHIBITOR 10 (ALISKIREN) | GLYCOPROTEIN, INHIBITOR-COMPLEX, ASPARTYL PROTEASE, ZYMOGEN, PROTEASE, HYDROLASE, POLYMORPHISM, ALTERNATIVE SPLICING, HYDROLASE(ACID PROTEINASE), CLEAVAGE ON PAIR OF BASIC RESIDUES
1flh:A (ASP2) to (PRO41) CRYSTAL STRUCTURE OF HUMAN UROPEPSIN AT 2.45 A RESOLUTION | ACID PROTEINASE, HYDROLASE
4ze6:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT B39 | FRAGMENT SCREENING, ASPARTIC PROTEASE INHIBITION, HYDROLASE
2vnm:A (ASN66) to (GLY102) HUMAN BACE-1 IN COMPLEX WITH 3-(1,1-DIOXIDOTETRAHYDRO-2H-1, 2-THIAZIN-2-YL)-5-(ETHYLAMINO)-N-((1S,2R)-2-HYDROXY-1-( PHENYLMETHYL)-3-(((3-(TRIFLUOROMETHYL)PHENYL)METHYL)AMINO) PROPYL)BENZAMIDE | HYDROLASE, ALTERNATIVE SPLICING, BETA-SITE APP CLEAVING ENZYME, BETA-SECRETASE, ASPARTYL PROTEASE, ASP-2, BACE-1, ZYMOGEN, PROTEASE, MEMBRANE, MEMAPSIN-2, GLYCOPROTEIN, TRANSMEMBRANE
2g1r:A (SER3) to (PRO42) KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING | PROTEIN-LIGAND COMPLEXES, HYDROLASE
2g1r:B (SER3) to (PRO42) KETOPIPERAZINE-BASED RENIN INHIBITORS: OPTIMIZATION OF THE C RING | PROTEIN-LIGAND COMPLEXES, HYDROLASE
1st8:A (PRO203) to (PRO253) CRYSTAL STRUCTURE OF FRUCTAN 1-EXOHYDROLASE IIA FROM CICHORIUM INTYBUS | FIVE FOLD BETA PROPELLER, HYDROLASE
2wed:A (ALA1) to (PHE42) ACID PROTEINASE (PENICILLOPEPSIN) (E.C.3.4.23.20) COMPLEX WITH PHOSPHONATE MACROCYCLIC INHIBITOR:METHYL[CYCLO-7[(2R)- ((N-VALYL)AMINO)-2-(HYDROXYL-(1S)-1-METHYOXYCARBONYL-2- PHENYLETHOXY)PHOSPHINYLOXY-ETHYL]-1-NAPHTHALENEACETAMIDE], SODIUM SALT | PENICILLOPEPSIN, MACROCYCLIC INHIBITOR, HYDROLASE
1i4e:A (LEU217) to (LYS263) CRYSTAL STRUCTURE OF THE CASPASE-8/P35 COMPLEX | COVALENT COMPLEX PROTEASE-INHIBITOR, APOPTOSIS-HYDROLASE COMPLEX
1uh9:A (GLY4) to (ALA44) CRYSTAL STRUCTURE OF RHIZOPUSPEPSIN AT PH 7.0 | PEPSIN, ASPARTIC PROTEINASE, HYDROLASE
3wb5:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BETA SECETASE IN COMPLEX WITH (6S)-2-AMINO-3,6- DIMETHYL-6-[(1R,2R)-2-PHENYLCYCLOPROPYL]-3,4,5,6-TETRAHYDROPYRIMIDIN- 4-ONE | PROTEASE 2, ASP2, MEMBRANE-ASSOCIATED ASPARTIC PROTEASE 2, MEMAPSIN- 2, HYDROLASE
2jjj:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A GEM-DIOL INHIBITOR. | ACID PROTEINASE, ASPARTYL PROTEASE, ZYMOGEN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3zov:A (ASN66) to (GLY102) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH CHEMICAL LIGAND | HYDROLASE
1lee:A (ASP4) to (PRO43) CRYSTAL STRUCTURE OF PLASMEPSIN FROM P. FALCIPARUM IN COMPLEX WITH INHIBITOR RS367 | PLASMEPSIN, ASPARTIC PROTEASE, PLASMODIUM FALCIPARUM, HYDROLASE
3k1w:A (ASN5) to (PRO47) NEW CLASSES OF POTENT AND BIOAVAILABLE HUMAN RENIN INHIBITORS | RENIN, PROTEASE, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, CLEAVAGE ON PAIR OF BASIC RESIDUES, DISEASE MUTATION, DISULFIDE BOND, GLYCOPROTEIN, HYDROLASE, MEMBRANE, POLYMORPHISM, SECRETED, ZYMOGEN
2zji:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF THE HUMAN BACE1 CATALYTIC DOMAIN IN COMPLEX WITH N-[1-(2,6-DIMETHOXY-BENZYL)-PIPERIDIN-4-YL]-4-MERCAPTO-BUTYRAMIDE | BACE1, SMALL-MOLECULE INHIBITOR, ASPARTYL PROTEASE, GLYCOPROTEIN, HYDROLASE, MEMBRANE, PROTEASE, TRANSMEMBRANE, ZYMOGEN
4acu:A (ASN5) to (ALA43) AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 14 | HYDROLASE, ALZHEIMER'S DISEASE
4acx:A (ASN5) to (ALA43) AMINOIMIDAZOLES AS BACE-1 INHIBITORS. X-RAY CRYSTAL STRUCTURE OF BETA SECRETASE COMPLEXED WITH COMPOUND 23 | HYDROLASE, ALZHEIMER'S DISEASE
1y4w:A (GLU241) to (ASP292) CRYSTAL STRUCTURE OF EXO-INULINASE FROM ASPERGILLUS AWAMORI IN SPACEGROUP P21 | EXO-INULINASE, ASPERGILLUS AWAMORI, GLYCOSIDE HYDROLASE FAMILY 32, CRYSTALLOGRAPHIC STRUCTURE, NATIVE STRUCTURE, HYDROLASE
3l5f:A (ASN66) to (GLY102) STRUCTURE OF BACE BOUND TO SCH736201 | BACE1, ALZHEIMERS, ALTERNATIVE SPLICING, ASPARTYL PROTEASE, DISULFIDE BOND, ENDOPLASMIC RETICULUM, ENDOSOME, GLYCOPROTEIN, GOLGI APPARATUS, HYDROLASE, MEMBRANE, POLYMORPHISM, PROTEASE, TRANSMEMBRANE, ZYMOGEN
5dq2:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 48 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dr3:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 333 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
5dr7:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH FRAGMENT 311 | FRAGMENT SCREENING, HYDROLASE, INHIBITION
4apr:E (GLY4) to (ALA44) STRUCTURES OF COMPLEXES OF RHIZOPUSPEPSIN WITH PEPSTATIN AND OTHER STATINE-CONTAINING INHIBITORS | ACID PROTEINASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4q1n:A (ASN-1) to (PRO41) STRUCTURE-BASED DESIGN OF 4-HYDROXY-3,5-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS | ASPARTIC PROTEASE, ANGIOTENSIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4q1n:B (ASN-1) to (PRO41) STRUCTURE-BASED DESIGN OF 4-HYDROXY-3,5-SUBSTITUTED PIPERIDINES AS DIRECT RENIN INHIBITORS | ASPARTIC PROTEASE, ANGIOTENSIN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4b78:A (ASN5) to (ALA43) AMINOIMIDAZOLES AS BACE-1 INHIBITORS: FROM DE NOVO DESIGN TO AB-LOWERING IN BRAIN | HYDROLASE, HYDROLASE INHIBITOR, LEAD GENERATION, STRUCTURE-BASED DRUG DESIGN
3ckp:C (ASN5) to (GLY41) CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH INHIBITOR | BETA-SECRETASE, ASPARTYL PROTEASE, ALTERNATIVE SPLICING, GLYCOPROTEIN, HYDROLASE, MEMBRANE, TRANSMEMBRANE, ZYMOGEN
4d83:A (ASN5) to (GLY41) CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436, DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT | BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4d83:B (ASN5) to (GLY41) CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436, DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT | BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4d83:C (ASN5) to (GLY41) CRYSTAL STRUCTURE OF HUMAN BETA SECRETASE IN COMPLEX WITH NVP-BUR436, DERIVED FROM A CO-CRYSTALLIZATION EXPERIMENT | BETA-SECRETASE, MEMAPSIN2, BACE1, ASPARTIC PROTEINASE, ALZHEIMER'S DISEASE, ENZYME INHIBITOR COMPLEX, STRUCTURE-BASED DRUG DESIGN, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
3pll:A (SER1) to (PHE44) ENDOTHIAPEPSIN IN COMPLEX WITH A FRAGMENT | HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gj6:A (ASN-1) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A) | RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
4gj6:B (THR0) to (PRO41) CRYSTAL STRUCTURE OF RENIN IN COMPLEX WITH NVP-AYZ832 (COMPOUND 6A) | RENIN INHIBITOR, PHARMACOPHORE SEARCH, TRANS-3,4-DISUBSTITUTED PYRROLIDINE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5kr8:A (ASN53) to (GLY89) (4~{S},6~{S})-4-[2,4-BIS(FLUORANYL)PHENYL]-6-(3,5-DIMETHYL-1,2-OXAZOL- 4-YL)-4-METHYL-5,6-DIHYDRO-1,3-THIAZIN-2-AMINE (COMPOUND 5) BOUND TO BACE1 | BACE-1, SMALL MOLECULE INHIBITOR, HYDROLASE-HYDROLASE INHIBITOR COMPLEX
5oz4:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 15 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5ozj:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 30 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p01:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 48 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p05:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 52 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 57 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 61 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p0w:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 79 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p13:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 86 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 95 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 100 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 106 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1o:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 107 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 109 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1t:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 112 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p1v:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 114 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 128 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2c:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 130 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2e:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 132 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 136 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2j:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 137 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 145 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p2y:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 151 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p39:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 162 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3a:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 163 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 168 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p3h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 170 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4n:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 212 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4u:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 219 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p4x:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 222 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p50:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 225 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p51:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 226 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p52:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 227 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p57:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 232 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 236 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p5p:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 250 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p60:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 261 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p67:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 268 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p69:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 270 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6b:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 272 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p6f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 276 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p73:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 300 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p74:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 301 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p79:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 306 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7f:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 312 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 313 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7h:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 314 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7k:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 317 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7l:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 318 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p7s:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 325 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8g:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 349 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8i:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 351 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5p8q:A (SER1) to (PHE44) AUTOMATED REFINEMENT OF DIFFRACTION DATA OBTAINED FROM AN ENDOTHIAPEPSIN CRYSTAL TREATED WITH FRAGMENT 359 | FRAGMENT SCREENING, METHOD DEVELOPMENT, ASPARTIC PROTEASE, HYDROLASE
5sy2:B (ILE11) to (PRO47) STRUCTURE-BASED DESIGN OF A NEW SERIES OF N-PIPERIDIN-3-YLPYRIMIDINE- 5-CARBOXAMIDES AS RENIN INHIBITORS | PROTEIN-LIGAND COMPLEX, HYDROLASE-HYDROLASE INHIBITOR COMPLEX